Shamburg News · 8-K filed Nov 12, 2026, 4:03 PM EST

CV Sciences Reports Third Quarter 2026 Revenue of $3.0 Million and Net Loss of $93,000

CVSI · CV Sciences, Inc.

  • Earnings
  • Reg FD disclosure
  • Materiality: high

On November 12, 2026, CV Sciences reported unaudited results for the quarter ended September 30, 2026, with product sales of $3.0 million, a decrease of 7.0% from $3.3 million in the third quarter of 2025. The company reported a GAAP net loss of $93 thousand, or $(0.00) per share, compared with a net loss of $382 thousand in the prior-year quarter, and positive adjusted EBITDA of $32 thousand. Operating income included a $500 thousand gain on legal settlement.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, accession 0001193125-26-458290.

Written from the filing by Shamburg Markets. Figures are as reported by the company.